Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108118
Title:
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.
Authors:
Bronchud, M; Scarffe, J Howard; Thatcher, Nick; Crowther, Derek; Souza, L M; Alton, N K; Testa, Nydia G; Dexter, T Michael
Abstract:
Twelve patients with advanced small cell carcinoma of the bronchus were treated by continuous infusion of recombinant human granulocyte colony-stimulating factor (rh G-CSF) at the following dose levels: 1 microgram, 5 micrograms, 10 micrograms, 20 micrograms and 40 micrograms/kg/day for 5 days. No toxicities resulted from the treatment and in all 12 patients the number of peripheral neutrophils increased rapidly to a maximum of 100 x 10(9)/l in one patient at 10 micrograms/kg/day. The neutrophils were shown to be functionally normal in tests of their mobility and bactericidal activity. During the Phase II part of the patients were treated using a combination of i.v. Adriamycin, Ifosfamide and Etoposide. The chemotherapy was repeated every 3 weeks. rh G-CSF was given to each patient for 14 days on alternate cycles of chemotherapy and reduced the period of absolute neutropenia considerably (median of 80%), with a return to normal, or above normal, neutrophil counts within 2 weeks after day 1 of chemotherapy. Ten severe infective episodes were observed during the 20 cycles of chemotherapy which did not include rh G-CSF, while only one infective episode occurred in 20 courses when treated with rh G-CSF. These results demonstrate the utility of rh G-CSF in restoring functional neutrophils to patients undergoing intensive chemotherapy.
Affiliation:
Cancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester, U.K.
Citation:
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. 1988 (83):327-9 Behring Inst. Mitt.
Journal:
Behring Institute Mitteilungen
Issue Date:
Aug-1988
URI:
http://hdl.handle.net/10541/108118
PubMed ID:
2467655
Type:
Article
Language:
en
ISSN:
0301-0457
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorBronchud, Men
dc.contributor.authorScarffe, J Howarden
dc.contributor.authorThatcher, Nicken
dc.contributor.authorCrowther, Dereken
dc.contributor.authorSouza, L Men
dc.contributor.authorAlton, N Ken
dc.contributor.authorTesta, Nydia Gen
dc.contributor.authorDexter, T Michaelen
dc.date.accessioned2010-07-21T16:19:51Z-
dc.date.available2010-07-21T16:19:51Z-
dc.date.issued1988-08-
dc.identifier.citationPhase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. 1988 (83):327-9 Behring Inst. Mitt.en
dc.identifier.issn0301-0457-
dc.identifier.pmid2467655-
dc.identifier.urihttp://hdl.handle.net/10541/108118-
dc.description.abstractTwelve patients with advanced small cell carcinoma of the bronchus were treated by continuous infusion of recombinant human granulocyte colony-stimulating factor (rh G-CSF) at the following dose levels: 1 microgram, 5 micrograms, 10 micrograms, 20 micrograms and 40 micrograms/kg/day for 5 days. No toxicities resulted from the treatment and in all 12 patients the number of peripheral neutrophils increased rapidly to a maximum of 100 x 10(9)/l in one patient at 10 micrograms/kg/day. The neutrophils were shown to be functionally normal in tests of their mobility and bactericidal activity. During the Phase II part of the patients were treated using a combination of i.v. Adriamycin, Ifosfamide and Etoposide. The chemotherapy was repeated every 3 weeks. rh G-CSF was given to each patient for 14 days on alternate cycles of chemotherapy and reduced the period of absolute neutropenia considerably (median of 80%), with a return to normal, or above normal, neutrophil counts within 2 weeks after day 1 of chemotherapy. Ten severe infective episodes were observed during the 20 cycles of chemotherapy which did not include rh G-CSF, while only one infective episode occurred in 20 courses when treated with rh G-CSF. These results demonstrate the utility of rh G-CSF in restoring functional neutrophils to patients undergoing intensive chemotherapy.en
dc.language.isoenen
dc.subjectHaemoglobinen
dc.subjectLung Canceren
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCarcinoma, Small Cell-
dc.subject.meshColony-Stimulating Factors-
dc.subject.meshDoxorubicin-
dc.subject.meshDrug Evaluation-
dc.subject.meshEtoposide-
dc.subject.meshGranulocyte Colony-Stimulating Factor-
dc.subject.meshHemoglobins-
dc.subject.meshHumans-
dc.subject.meshIfosfamide-
dc.subject.meshLeukocyte Count-
dc.subject.meshLung Neoplasms-
dc.subject.meshMesna-
dc.subject.meshNeutrophils-
dc.subject.meshPlatelet Count-
dc.subject.meshRecombinant Proteins-
dc.titlePhase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester, U.K.en
dc.identifier.journalBehring Institute Mitteilungenen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.